Functional imaging of thymic disorders

Secondo Lastoria, Giovannella Palmieri, Pietro Muto, Gaetano Lombardi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Human thymomas are rare tumours which usually develop in the chest. The diagnosis via guided biopsy, the evaluation of the extent of the tumour and its boundaries with adjacent organs, the choice of the appropriate therapeutic option, and the assessment of response to treatment are usually made with computed tomography (CT) alone or in combination with magnetic resonance imaging (MRI). More recently, radiopharmaceuticals and nuclear medicine procedures have been used increasingly in the imaging and functional characterization of benign and malignant thymic disorders. Two groups of radiopharmaceuticals have been used. The first includes several oncotropic tracers, such as 201Tl-chloride, 99mTc-sestamibi and 18F-fluorodeoxyglucose, which are significantly concentrated in thymic tumours. Their uptake correlates with tumour grades and cellularity. The second class includes two radioligands: [111In-DTPA-D-Phe1]-octreotide (DTPA, diethylenetriamine penta-acetic acid) and [111In-DTPA-Arg1]-substance P, which bind to specific receptors. [111In-DTPA-Arg1]-substance P binds to its receptors that are largely expressed in the thymus of patients with autoimmune diseases. [111In-DTPA-D-Phe1]-octreotide recognizes the somatostatin receptor subtype 2. In patients with active disease investigated in our institution [111In-DTPA-D-Phe1]-octreotide has been shown to concentrate in the majority of thymoma deposits. Conversely, it is not concentrated in adult patients with benign lymphofollicular thymic hyperplasia. This finding has had a significant impact on the management of patients with myasthenia gravis as it differentiates early-stage thymoma from benign hyperplasia, unlike CT and MRI, which often fail to distinguish between the two. In addition to its role in diagnostic imaging, somatostatin receptor scintigraphy also enables us to select patients with advanced or metastatic thymoma unresponsive to conventional therapies, who might benefit from a somatostatin analogue-based treatment, serving thus as a link between diagnosis and therapy In this article, we discuss and analyse the results of functional imaging with different radiopharmaceuticals, primarily those that we have obtained with [111In-DTPA-D-Phe1]-octreotide.

Original languageEnglish
Pages (from-to)63-69
Number of pages7
JournalAnnals of Medicine
Volume31
Issue numberSUPPL. 2
Publication statusPublished - Oct 1999

Fingerprint

Rubiaceae
Acetic Acid
Octreotide
Thymoma
Radiopharmaceuticals
Substance P
Thymus Hyperplasia
Tomography
Magnetic Resonance Imaging
Thymus Neoplasms
Technetium Tc 99m Sestamibi
Therapeutics
Neoplasms
Somatostatin Receptors
Myasthenia Gravis
Nuclear Medicine
Fluorodeoxyglucose F18
Diagnostic Imaging
diethylenetriamine
Somatostatin

Keywords

  • [In-DTPA-D-Phe]-octreotide
  • Radiolabelled peptides
  • Somatostatin receptor scintigraphy
  • Thymic benign hyperplasia
  • Thymic tumours

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lastoria, S., Palmieri, G., Muto, P., & Lombardi, G. (1999). Functional imaging of thymic disorders. Annals of Medicine, 31(SUPPL. 2), 63-69.

Functional imaging of thymic disorders. / Lastoria, Secondo; Palmieri, Giovannella; Muto, Pietro; Lombardi, Gaetano.

In: Annals of Medicine, Vol. 31, No. SUPPL. 2, 10.1999, p. 63-69.

Research output: Contribution to journalArticle

Lastoria, S, Palmieri, G, Muto, P & Lombardi, G 1999, 'Functional imaging of thymic disorders', Annals of Medicine, vol. 31, no. SUPPL. 2, pp. 63-69.
Lastoria S, Palmieri G, Muto P, Lombardi G. Functional imaging of thymic disorders. Annals of Medicine. 1999 Oct;31(SUPPL. 2):63-69.
Lastoria, Secondo ; Palmieri, Giovannella ; Muto, Pietro ; Lombardi, Gaetano. / Functional imaging of thymic disorders. In: Annals of Medicine. 1999 ; Vol. 31, No. SUPPL. 2. pp. 63-69.
@article{707cd27dc6f7449abdefd3efd49c6579,
title = "Functional imaging of thymic disorders",
abstract = "Human thymomas are rare tumours which usually develop in the chest. The diagnosis via guided biopsy, the evaluation of the extent of the tumour and its boundaries with adjacent organs, the choice of the appropriate therapeutic option, and the assessment of response to treatment are usually made with computed tomography (CT) alone or in combination with magnetic resonance imaging (MRI). More recently, radiopharmaceuticals and nuclear medicine procedures have been used increasingly in the imaging and functional characterization of benign and malignant thymic disorders. Two groups of radiopharmaceuticals have been used. The first includes several oncotropic tracers, such as 201Tl-chloride, 99mTc-sestamibi and 18F-fluorodeoxyglucose, which are significantly concentrated in thymic tumours. Their uptake correlates with tumour grades and cellularity. The second class includes two radioligands: [111In-DTPA-D-Phe1]-octreotide (DTPA, diethylenetriamine penta-acetic acid) and [111In-DTPA-Arg1]-substance P, which bind to specific receptors. [111In-DTPA-Arg1]-substance P binds to its receptors that are largely expressed in the thymus of patients with autoimmune diseases. [111In-DTPA-D-Phe1]-octreotide recognizes the somatostatin receptor subtype 2. In patients with active disease investigated in our institution [111In-DTPA-D-Phe1]-octreotide has been shown to concentrate in the majority of thymoma deposits. Conversely, it is not concentrated in adult patients with benign lymphofollicular thymic hyperplasia. This finding has had a significant impact on the management of patients with myasthenia gravis as it differentiates early-stage thymoma from benign hyperplasia, unlike CT and MRI, which often fail to distinguish between the two. In addition to its role in diagnostic imaging, somatostatin receptor scintigraphy also enables us to select patients with advanced or metastatic thymoma unresponsive to conventional therapies, who might benefit from a somatostatin analogue-based treatment, serving thus as a link between diagnosis and therapy In this article, we discuss and analyse the results of functional imaging with different radiopharmaceuticals, primarily those that we have obtained with [111In-DTPA-D-Phe1]-octreotide.",
keywords = "[In-DTPA-D-Phe]-octreotide, Radiolabelled peptides, Somatostatin receptor scintigraphy, Thymic benign hyperplasia, Thymic tumours",
author = "Secondo Lastoria and Giovannella Palmieri and Pietro Muto and Gaetano Lombardi",
year = "1999",
month = "10",
language = "English",
volume = "31",
pages = "63--69",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Functional imaging of thymic disorders

AU - Lastoria, Secondo

AU - Palmieri, Giovannella

AU - Muto, Pietro

AU - Lombardi, Gaetano

PY - 1999/10

Y1 - 1999/10

N2 - Human thymomas are rare tumours which usually develop in the chest. The diagnosis via guided biopsy, the evaluation of the extent of the tumour and its boundaries with adjacent organs, the choice of the appropriate therapeutic option, and the assessment of response to treatment are usually made with computed tomography (CT) alone or in combination with magnetic resonance imaging (MRI). More recently, radiopharmaceuticals and nuclear medicine procedures have been used increasingly in the imaging and functional characterization of benign and malignant thymic disorders. Two groups of radiopharmaceuticals have been used. The first includes several oncotropic tracers, such as 201Tl-chloride, 99mTc-sestamibi and 18F-fluorodeoxyglucose, which are significantly concentrated in thymic tumours. Their uptake correlates with tumour grades and cellularity. The second class includes two radioligands: [111In-DTPA-D-Phe1]-octreotide (DTPA, diethylenetriamine penta-acetic acid) and [111In-DTPA-Arg1]-substance P, which bind to specific receptors. [111In-DTPA-Arg1]-substance P binds to its receptors that are largely expressed in the thymus of patients with autoimmune diseases. [111In-DTPA-D-Phe1]-octreotide recognizes the somatostatin receptor subtype 2. In patients with active disease investigated in our institution [111In-DTPA-D-Phe1]-octreotide has been shown to concentrate in the majority of thymoma deposits. Conversely, it is not concentrated in adult patients with benign lymphofollicular thymic hyperplasia. This finding has had a significant impact on the management of patients with myasthenia gravis as it differentiates early-stage thymoma from benign hyperplasia, unlike CT and MRI, which often fail to distinguish between the two. In addition to its role in diagnostic imaging, somatostatin receptor scintigraphy also enables us to select patients with advanced or metastatic thymoma unresponsive to conventional therapies, who might benefit from a somatostatin analogue-based treatment, serving thus as a link between diagnosis and therapy In this article, we discuss and analyse the results of functional imaging with different radiopharmaceuticals, primarily those that we have obtained with [111In-DTPA-D-Phe1]-octreotide.

AB - Human thymomas are rare tumours which usually develop in the chest. The diagnosis via guided biopsy, the evaluation of the extent of the tumour and its boundaries with adjacent organs, the choice of the appropriate therapeutic option, and the assessment of response to treatment are usually made with computed tomography (CT) alone or in combination with magnetic resonance imaging (MRI). More recently, radiopharmaceuticals and nuclear medicine procedures have been used increasingly in the imaging and functional characterization of benign and malignant thymic disorders. Two groups of radiopharmaceuticals have been used. The first includes several oncotropic tracers, such as 201Tl-chloride, 99mTc-sestamibi and 18F-fluorodeoxyglucose, which are significantly concentrated in thymic tumours. Their uptake correlates with tumour grades and cellularity. The second class includes two radioligands: [111In-DTPA-D-Phe1]-octreotide (DTPA, diethylenetriamine penta-acetic acid) and [111In-DTPA-Arg1]-substance P, which bind to specific receptors. [111In-DTPA-Arg1]-substance P binds to its receptors that are largely expressed in the thymus of patients with autoimmune diseases. [111In-DTPA-D-Phe1]-octreotide recognizes the somatostatin receptor subtype 2. In patients with active disease investigated in our institution [111In-DTPA-D-Phe1]-octreotide has been shown to concentrate in the majority of thymoma deposits. Conversely, it is not concentrated in adult patients with benign lymphofollicular thymic hyperplasia. This finding has had a significant impact on the management of patients with myasthenia gravis as it differentiates early-stage thymoma from benign hyperplasia, unlike CT and MRI, which often fail to distinguish between the two. In addition to its role in diagnostic imaging, somatostatin receptor scintigraphy also enables us to select patients with advanced or metastatic thymoma unresponsive to conventional therapies, who might benefit from a somatostatin analogue-based treatment, serving thus as a link between diagnosis and therapy In this article, we discuss and analyse the results of functional imaging with different radiopharmaceuticals, primarily those that we have obtained with [111In-DTPA-D-Phe1]-octreotide.

KW - [In-DTPA-D-Phe]-octreotide

KW - Radiolabelled peptides

KW - Somatostatin receptor scintigraphy

KW - Thymic benign hyperplasia

KW - Thymic tumours

UR - http://www.scopus.com/inward/record.url?scp=0032730865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032730865&partnerID=8YFLogxK

M3 - Article

C2 - 10574158

AN - SCOPUS:0032730865

VL - 31

SP - 63

EP - 69

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - SUPPL. 2

ER -